HUE067827T2 - Új inzulin analógok és alkalmazásaik - Google Patents

Új inzulin analógok és alkalmazásaik

Info

Publication number: HUE067827T2
Authority: HU; Hungary
Prior art keywords: applications; insulin analogues; new insulin; new; analogues
Prior art date: 2019-12-11

Application number

HUE20820432A

Other languages

English (en)

Inventor

Frantisek Hubalek

Mathias Norrman

Helle Olsen

Peter Madsen

Thomas Kjeldsen

Jeppe Sturis

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-12-11

Filing date

2020-12-10

Publication date

2024-11-28

2020-12-10 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2024-11-28 Publication of HUE067827T2 publication Critical patent/HUE067827T2/hu

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Diabetes (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Oil, Petroleum & Natural Gas (AREA)
Immunology (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

HUE20820432A 2019-12-11 2020-12-10 Új inzulin analógok és alkalmazásaik HUE067827T2 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP19215315		2019-12-11

Publications (1)

Publication Number	Publication Date
HUE067827T2 true HUE067827T2 (hu)	2024-11-28

Family

ID=68886882

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUE20820432A HUE067827T2 (hu)	2019-12-11	2020-12-10	Új inzulin analógok és alkalmazásaik

Country Status (28)

Country	Link
US (3)	US11498951B2 (hu)
EP (2)	EP4480492A3 (hu)
JP (2)	JP6995284B2 (hu)
KR (1)	KR102427426B1 (hu)
CN (1)	CN114787184A (hu)
AR (1)	AR120717A1 (hu)
AU (1)	AU2020402135A1 (hu)
BR (1)	BR112022009510A2 (hu)
CA (1)	CA3159114A1 (hu)
CL (1)	CL2023000086A1 (hu)
CO (1)	CO2022007273A2 (hu)
DK (1)	DK4073097T3 (hu)
ES (1)	ES2985989T3 (hu)
FI (1)	FI4073097T3 (hu)
HR (1)	HRP20241042T1 (hu)
HU (1)	HUE067827T2 (hu)
IL (2)	IL292762A (hu)
LT (1)	LT4073097T (hu)
MA (1)	MA58093B1 (hu)
MX (2)	MX2022006251A (hu)
PE (1)	PE20221260A1 (hu)
PH (1)	PH12022551094A1 (hu)
PL (1)	PL4073097T3 (hu)
PT (1)	PT4073097T (hu)
RS (1)	RS65822B1 (hu)
SI (1)	SI4073097T1 (hu)
TW (1)	TWI773009B (hu)
WO (1)	WO2021116292A1 (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2016311283B2 (en)	2015-08-25	2020-10-08	Novo Nordisk A/S	Novel insulin derivatives and the medical uses hereof
CN114787184A (zh) *	2019-12-11	2022-07-22	诺和诺德股份有限公司	新型胰岛素类似物及其用途
KR20230057686A (ko)	2021-10-22	2023-05-02	주식회사 엘지에너지솔루션	캡 어셈블리 및 이를 포함하는 이차 전지

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PH25772A (en) *	1985-08-30	1991-10-18	Novo Industri As	Insulin analogues, process for their preparation
DK105489D0 (da)	1989-03-03	1989-03-03	Novo Nordisk As	Polypeptid
AU641721B2 (en)	1989-12-21	1993-09-30	Novo Nordisk A/S	Insulin preparations containing nicotinic acid or nicotinamide
SK282495B6 (sk)	1993-09-17	2002-02-05	Novo Nordisk A/S	Acylovaný inzulínový derivát a farmaceutický prostriedok, ktorý ho obsahuje
IL114160A (en)	1994-06-17	2006-12-31	Novo Nordisk As	Dna constructs encoding heterologous proteins and processes for the heterologous protein production in yeast
US6500645B1 (en)	1994-06-17	2002-12-31	Novo Nordisk A/S	N-terminally extended proteins expressed in yeast
US5922678A (en)	1996-06-28	1999-07-13	Eli Lilly And Company	Methods for treating diabetes
AU7873798A (en)	1996-12-20	1998-07-17	Novo Nordisk A/S	N-terminally extended proteins expressed in yeast
KR20000076419A (ko)	1997-03-20	2000-12-26	한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느	폐 투여용 무아연 인슐린 결정 조성물
EA200000453A1 (ru)	1997-10-24	2000-10-30	Эли Лилли Энд Компани	Композиции нерастворимого инсулина
DE10114178A1 (de)	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US7193035B2 (en)	2002-10-29	2007-03-20	Sanofi-Aventis Deutschland Gmbh	Crystals of insulin analogs and processes for their preparation
CN1902226A (zh)	2003-12-03	2007-01-24	诺和诺德公司	单链胰岛素
US20100216690A1 (en)	2005-03-18	2010-08-26	Novo Nordisk A/S	Pegylated Single-Chain Insulin
EP1991576B1 (en)	2006-02-27	2010-09-29	Novo Nordisk A/S	Insulin derivatives
JP2009530243A (ja)	2006-03-13	2009-08-27	ノボ・ノルデイスク・エー／エス	アシル化単鎖インスリン
ITRG20070003A1 (it)	2007-07-17	2009-01-18	Salvatore Lucifora	Metodo e sistema informatico per analizzare le prestazioni e dimensionare una cella underlay/overlay di un sistema di telecomunicazione cellulare
CN101778862B (zh)	2007-08-13	2014-12-17	诺沃-诺迪斯克有限公司	快速作用的胰岛素类似物
AU2008288413B2 (en)	2007-08-15	2013-09-26	Novo Nordisk A/S	Insulin analogues with an acyl and aklylene glycol moiety
JP5721432B2 (ja)	2007-08-15	2015-05-20	ノボ・ノルデイスク・エー／エス	アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
WO2009112583A2 (en)	2008-03-14	2009-09-17	Novo Nordisk A/S	Protease-stabilized insulin analogues
PT2910570T (pt)	2008-03-18	2017-01-24	Novo Nordisk As	Análogos de insulina acilados, estabilizados contra proteases
WO2009121884A1 (en)	2008-04-01	2009-10-08	Novo Nordisk A/S	Insulin albumin conjugates
EP2448962B1 (en)	2009-06-30	2016-10-19	Novo Nordisk A/S	Insulin derivatives
CN102665676B (zh)	2009-11-02	2015-04-01	诺沃-诺迪斯克有限公司	非共价结合的白蛋白和酰化胰岛素的药物溶液
JP5973427B2 (ja)	2010-06-23	2016-08-23	ノヴォノルディスクアー／エス	追加のジスルフィド結合を含有するインスリン類似体
EP2598522A4 (en)	2010-07-28	2014-11-12	Smartcells Inc	RECOMBINANT LECTINES, LECTINES WITH MODIFIED BINDING SITE AND USES THEREOF
EP2627670A2 (en)	2010-10-15	2013-08-21	Novo Nordisk A/S	Novel n-terminally modified insulin derivatives
WO2012171994A1 (en)	2011-06-15	2012-12-20	Novo Nordisk A/S	Multi substituted insulins
EP2771026A4 (en)	2011-10-27	2015-08-05	Univ Case Western Reserve	ULTRA-CONCENTRATED AND FAST-ACTING INSULIN ANALOG FORMULATIONS
CN104788556A (zh)	2011-12-15	2015-07-22	上海恒瑞医药有限公司	人胰岛素类似物及其酰化衍生物
WO2014158900A1 (en)	2013-03-14	2014-10-02	Indiana University Research And Technology Corporation	Insulin-incretin conjugates
US9884125B2 (en)	2013-10-04	2018-02-06	Merck Sharp & Dohme Corp.	Glucose-responsive insulin conjugates
AR099569A1 (es)	2014-02-28	2016-08-03	Novo Nordisk As	Derivados de insulina y los usos médicos de estos
CN108026156A (zh) *	2015-08-25	2018-05-11	诺和诺德股份有限公司	新型胰岛素衍生物及其医学用途
AU2016311283B2 (en)	2015-08-25	2020-10-08	Novo Nordisk A/S	Novel insulin derivatives and the medical uses hereof
CN105440125B (zh)	2015-11-25	2019-09-24	华润昂德生物药业有限公司	地特胰岛素或其类似物的制备方法
EP3740212A4 (en)	2017-12-18	2021-10-27	Merck Sharp & Dohme Corp.	CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
CN114787184A (zh)	2019-12-11	2022-07-22	诺和诺德股份有限公司	新型胰岛素类似物及其用途

2020
- 2020-12-10 CN CN202080085447.7A patent/CN114787184A/zh active Pending
- 2020-12-10 IL IL292762A patent/IL292762A/en unknown
- 2020-12-10 MA MA58093A patent/MA58093B1/fr unknown
- 2020-12-10 PT PT208204321T patent/PT4073097T/pt unknown
- 2020-12-10 TW TW109143686A patent/TWI773009B/zh active
- 2020-12-10 DK DK20820432.1T patent/DK4073097T3/da active
- 2020-12-10 FI FIEP20820432.1T patent/FI4073097T3/fi active
- 2020-12-10 PE PE2022000971A patent/PE20221260A1/es unknown
- 2020-12-10 EP EP24185667.3A patent/EP4480492A3/en active Pending
- 2020-12-10 JP JP2020204804A patent/JP6995284B2/ja active Active
- 2020-12-10 LT LTEPPCT/EP2020/085541T patent/LT4073097T/lt unknown
- 2020-12-10 CA CA3159114A patent/CA3159114A1/en active Pending
- 2020-12-10 WO PCT/EP2020/085541 patent/WO2021116292A1/en active Application Filing
- 2020-12-10 IL IL319162A patent/IL319162A/en unknown
- 2020-12-10 AR ARP200103438A patent/AR120717A1/es unknown
- 2020-12-10 PL PL20820432.1T patent/PL4073097T3/pl unknown
- 2020-12-10 EP EP20820432.1A patent/EP4073097B1/en active Active
- 2020-12-10 BR BR112022009510A patent/BR112022009510A2/pt unknown
- 2020-12-10 RS RS20240887A patent/RS65822B1/sr unknown
- 2020-12-10 AU AU2020402135A patent/AU2020402135A1/en active Pending
- 2020-12-10 SI SI202030473T patent/SI4073097T1/sl unknown
- 2020-12-10 PH PH1/2022/551094A patent/PH12022551094A1/en unknown
- 2020-12-10 HR HRP20241042TT patent/HRP20241042T1/hr unknown
- 2020-12-10 HU HUE20820432A patent/HUE067827T2/hu unknown
- 2020-12-10 KR KR1020217035811A patent/KR102427426B1/ko active Active
- 2020-12-10 ES ES20820432T patent/ES2985989T3/es active Active
- 2020-12-10 US US17/117,263 patent/US11498951B2/en active Active
- 2020-12-10 MX MX2022006251A patent/MX2022006251A/es unknown
2021
- 2021-05-10 JP JP2021079614A patent/JP2021119193A/ja active Pending
2022
- 2022-05-24 MX MX2023000398A patent/MX2023000398A/es unknown
- 2022-05-27 CO CONC2022/0007273A patent/CO2022007273A2/es unknown
- 2022-10-06 US US17/961,438 patent/US12152063B2/en active Active
2023
- 2023-01-09 CL CL2023000086A patent/CL2023000086A1/es unknown
- 2023-12-15 US US18/541,682 patent/US12122818B2/en active Active

Also Published As

Publication number	Publication date
SI4073097T1 (sl)	2024-09-30
BR112022009510A2 (pt)	2022-08-16
US11498951B2 (en)	2022-11-15
PL4073097T3 (pl)	2024-10-28
MX2022006251A (es)	2022-06-22
KR20210141748A (ko)	2021-11-23
US12152063B2 (en)	2024-11-26
EP4480492A2 (en)	2024-12-25
KR102427426B1 (ko)	2022-08-01
PH12022551094A1 (en)	2024-06-24
MA58093B1 (fr)	2024-09-30
TWI773009B (zh)	2022-08-01
PT4073097T (pt)	2024-08-16
CL2023000086A1 (es)	2023-08-04
AU2020402135A1 (en)	2022-06-02
AR120717A1 (es)	2022-03-09
MX2023000398A (es)	2023-02-02
EP4480492A3 (en)	2025-03-19
US20240141011A1 (en)	2024-05-02
IL292762A (en)	2022-07-01
LT4073097T (lt)	2024-09-10
US20210179685A1 (en)	2021-06-17
TW202136289A (zh)	2021-10-01
JP6995284B2 (ja)	2022-01-14
IL319162A (en)	2025-04-01
JP2021091685A (ja)	2021-06-17
EP4073097B1 (en)	2024-07-03
CA3159114A1 (en)	2021-06-17
CN114787184A (zh)	2022-07-22
DK4073097T3 (da)	2024-08-19
FI4073097T3 (fi)	2024-08-13
CO2022007273A2 (es)	2022-08-19
RS65822B1 (sr)	2024-09-30
ES2985989T3 (es)	2024-11-08
PE20221260A1 (es)	2022-08-16
WO2021116292A1 (en)	2021-06-17
US20230192801A1 (en)	2023-06-22
EP4073097A1 (en)	2022-10-19
HRP20241042T1 (hr)	2024-11-08
JP2021119193A (ja)	2021-08-12
US12122818B2 (en)	2024-10-22

Publication	Publication Date	Title
HUE066356T2 (hu)	2024-07-28	GLP-1 készítmények és alkalmazásaik
IL284835A (en)	2021-08-31	Pharmaceutical combination comprising tno155 and ribociclib
HUE065882T2 (hu)	2024-06-28	Interleukin-2-polipeptid-konjugátumok és alkalmazásaik
HUE046621T2 (hu)	2020-03-30	Promóter szekvencia és alkalmazásai
HUE064136T2 (hu)	2024-02-28	PD-L1 variáns immunmódosító fehérjék és alkalmazásuk
HUE062927T2 (hu)	2023-12-28	Anti-TIGIT ellenanyagok és alkalmazási eljárásaik
HUE065255T2 (hu)	2024-05-28	Kódolási eljárás és kódoló berendezés
HUE058975T2 (hu)	2022-09-28	CD73-ellenes antitestek és alkalmazásaik
HUE054103T2 (hu)	2021-08-30	Izokinolin-3-il-karboxamidok, ezek elõállítása és alkalmazása
HUE055755T2 (hu)	2021-12-28	Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk
HUE053366T2 (hu)	2021-06-28	Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk
HUE061253T2 (hu)	2023-06-28	Antitestek OX40 ellen és azok felhasználásai
HUE061437T2 (hu)	2023-06-28	A Sestrin-GATOR2 kölcsönhatás modulátorai és ezek alkalmazásai
DK3322430T3 (da)	2020-06-29	Antiinflammatoriske peptider, og anvendelser deraf
HUE067827T2 (hu)	2024-11-28	Új inzulin analógok és alkalmazásaik
HUE063848T2 (hu)	2024-02-28	LSD1 gátlók és gyógyászati alkalmazásaik
HUE063120T2 (hu)	2023-12-28	LRRC33-inhibitorok és alkalmazásuk
HUE060805T2 (hu)	2023-04-28	Piridinamin-piridon és pirimidinamin-piridon vegyületek
HUE062893T2 (hu)	2023-12-28	Stabil szemaglutid kompozíciók, és alkalmazásaik
EP3820549A4 (en)	2022-04-20	SYRINGE SET
EP3746155A4 (en)	2021-10-27	SYRINGE SET
HUE063621T2 (hu)	2024-01-28	ß-interferon elleni ellenanyagok és alkalmazásuk
HUE062796T2 (hu)	2023-12-28	Megnövelt biológiai hozzáférhetõséggel rendelkezõ vegyületforma és annak készítményei
EP3351533A4 (en)	2019-03-06	BIARY DERIVATIVE AND MEDICAMENT THEREOF
HUE054822T2 (hu)	2021-10-28	Triciklusos vegyület és ennek alkalmazásai